[1] R. A. Cohen, K. M. Zitnay, C. C. Haudenschild and L. D. Cunningham, “Loss of Selective Endothelial Cell Vasoactive Functions Caused by Hypercholesterinemia in Pig Coronary Arteries,” Circulation Research, Vol. 63, No. 5, 1988, pp. 903-910.
[2] E. Barret-Connor and K. T. Khaw, “A Prospective Study of Dehydroepiandrosterone Sulfate Mortality and Cardiovascular Disease,” New England Journal of Medicine, Vol. 315, No. 24, 1986, pp. 1519-1524.
[3] E. E. Baulieu, “Dehydroepiandrosterone (DHEA): A Fountain of Youth?” Journal of Clinical Endocrinology & Metabolism, Vol. 81, 1996, pp. 3147-3151. doi:10.1210/jc.81.9.3147
[4] A. J. Moralea, J. J. Nolan and J. C. Nelson, “YEN Ssc. Effects of Replacement Dose of Dehydroepiandrosterone in Men and Women of Advancing Age,” Journal of Clinical Endocrinology & Metabolism, Vol. 78, 1994, pp. 1360-1367. doi:10.1210/jc.78.6.1360
[5] K. T. Khaw, “Dehydroepiandrosterone, Dehydroepiandrosterone Sulphate and Cardiovascular Disease,” Journal of Endodontics, Vol. 150, 1996, pp. S149-S153.
[6] J. K. Gierse, S. D. Hauser, D. P. Creely, C. Koboldt, S. H. Rangwala, P. C. Isakson and K. Seibert, “Expression and Selective Inhibition of the Constitutive and Inducible Forms of Human Cyclooxygenase,” Biochemical Journal, Vol. 305, 1995, pp. 479-484.
[7] G. B. Gordon, D. Bush, H. F. Weisman, “Reduction of Artherosclerosis by Administration of Dehydroepiandrosterone,” Journal of Clinical Investigation, Vol. 82, No. 2, 1988, pp. 712-720. doi:10.1172/JCI113652
[8] D. M. Herrington, “Dehydroepiandrosterone and Coronary Atherosclerosis,” Annals of the New York Academy of Sciences, Vol. 774, 1995, pp. 271-280. doi:10.1111/j.1749-6632.1995.tb17387.x-i1
[9] P. T. Leese, R. C. Hubbard, A. Karim, P. C. Isakson, S. S. Yu and G. S. Geis, “Effects of Celecoxib, a Novel Cyclooxgenase-2-Inhibitor, on Platelet Function in Healthy Adults: A Randomised, Controlled Trial,” Journal of Clinical Pharmacology, Vol. 40, No. 2, 2000, pp. 124-132. doi:10.1177/00912700022008766
[10] J. C. Fr?lich, “Selektive Cyclooxygenasehemmer-Eine neue Generation von Antirheumatika,” Deutsches ?rzte- blatt, Vol. 47, No. 23, 1996, pp. 3100-3101.
[11] P. E. Lipsky and P. C. Isakson, “Outcome of Specific COX Inhibition in Rheumatoid Arthritis,” Journal of Rheumatology, Vol. 24, Suppl. 49, 1997, pp. 9-14.
[12] K. Seibert, Y. Zhang, K. Leahy, S. Hauser, J. Masferrer, W. Perkins, L. Lee and P. Isakson, “Pharmacological and Biochemical Demonstration of the Role of Cyclooxygenase 2 in Inflammation and Pain,” Proceedings of the National Academy of Sciences USA, Vol. 91, 1994, pp. 12013-12017
[13] J. C. Fr?lich, “A Classification of NSAID’s According to the Relative Inhibition of Cyclooxygenase Isoenzymes,” Journal of Pharmacological Sciences, Vol. 18, 1997, pp. 1-35.
[14] J. C. Fr?lich, “Prostaglandin Endoperoxide Syntherase Isoenzymes: The Clinical Relevance of Selective Inhibi- tion,” Annals of the Rheumatic Diseases, Vol. 82, 1995, pp. 712-720.
[15] J. C. Fr?lich and D. O. Stichtenoth, “Renal Side Effects of NSAID’s: Role of COX-1 and COX-2,” Selective Cox-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutical Potential, Springer, Berlin, 1998, pp. 87- 97.
[16] D. O. Stichtenoth, H. Zeidler and J. C. Fr?lich, “Neue Nichtsteroidale Antirheumatika: Selektive Hemmstoffe der Induzierbaren Cyclooxygenase,” Medizinische Klinik Vol. 93, 1998, pp. 407-415.
[17] D. O. Stichtenoth and J. C. Fr?lich, “COX-2 and the Kidneys,” Current Pharmaceutical Design, Vol. 6, No. 17, 2000, pp. 1737-1753.
[18] D. O. Stichtenoth and J. C. Fr?lich, “Therapie Mit Pr?ferentiellen und Spezifischen COX-2-Inhibitoren,” Internist, Vol. 42, 2001, pp. 421-426.
[19] R. C. Hubbard, D. L. Mehlisch, D. R. Jasper, M. J. Nugent, S. Yu and P. C. Isakson, “SC-58625, a Highly Selective Inhibitor of COX-2, Is an Effective Analgesic in an Acute Post-Surgial Pain Model,” Journal of Investigative Medicine, Vol. 44, 1996, p. 293A
[20] R. Jouve, I. Juhan-Vague, M. Aillaud, M. Serment-Jouve and H. Payan, “Comparison of the Effects of Aspirin and Indomethacin on Aortic Artherogenesis Induced in Rabbits,” Artherosclerosis, Vol. 42, 1982, pp. 319-321. doi:10.1016/0021-9150(82)90159-9
[21] L. S. Simon, A. Weaver, D. Y. Graham, et al., “Anti-Inflammatory and Upper Gastrointestinal Effects of Celecoxib in Rheumatoid Arthritis,” JAMA, Vol. 282, No. 20, 1999, pp. 1921-1928. doi:10.1001/jama.282.20.1921
[22] D. O. Stichtenoth and J. C. Fr?lich, “The Second Genera- tion of COX-2-Inhibitors,” Drugs, Vol. 63, No. 1, 2003, pp. 33-45. doi:10.2165/00003495-200363010-00003
[23] J. D. Morrow and L. J. Roberts II, “The Isoprostanes: Unique Bioactive Products of Lipid Peroxidation,” Progress in Lipid Researc, Vol. 36, No. 1, 1997, pp. 1-21. doi:10.1016/S0163-7827(97)00001-5
[24] J. D. Morrow and L. J. Roberts II, “The Isoprostanes, Current Knowledge and Directions for Future Research,” Biochemical Pharmacology, Vol. 51, No. 1, 1996, pp. 1-9. doi:10.1016/0006-2952(95)02072-1
[25] S. M. Bode-B?ger, R. H. B?ger, S. Kienke, M. B?hme, L. Phivtongngam, D. Tsikas and J. C. Fr?lich, “Chronic Dietary Supplementation with L-Arginine Inhibits Platelet Aggregation and Thromboxane A2 Synthesis in Hypercholesteraemic Rabbits in Vivo,” Cardivascular Research, Vol. 37, 1998, pp. 756-764. doi:10.1016/S0008-6363(97)00295-2
[26] N. Delanty, M. Reilly, D. Practico, J. A. Lawson, J. F. Mc Carthy, “8-epi PGF2-Generation during Coronary Reperfusion,” Circulation, Vol. 95, 1997, pp. 2492-2499.
[27] D. O. Stichtenoth and J. C. Fr?lich, “COX-2 and the Kidneys,” Current Pharmaceutical Design, Vol. 6, No. 17, 2000, pp. 1737-1753.
[28] D. Tsikas, F.-M. Gutzki, M. B?hme, I. Fuchs and J. C. Fr?lich, “Solid- and Liquid-Phase Extraction for the Gas Chromatographic-Tandem Mass Spectrometric Quantification of 2,3-Dinor-thromboxane B2 and 2,3-Dinor-6-oxo-prostaglandin F1α in Human Urine,” Journal of Chromatography A, Vol. 885, 2000, pp. 351-359. doi:10.1016/S0021-9673(99)00967-X
[29] D. Tsikas, “Silmultaneus Derivazation and Quantification of the Nitric Oxide Metabolites Nitrite and Nitrate in Biological Fluids by Gas Chromatography/Mass Spectrometry,” Analytical Chemistry, Vol. 72, No. 17, 2000, pp. 4064-4072. doi:10.1021/ac9913255
[30] D. Practicó, L. Iuliano, L. Spagnioli, J. Maclouf, F. Violi, G. A. FitzGerald, “Monocytes in Human Artherosclerotic Plaque Contain Levels of 8-epi PGF2. An Index of Oxidative Stress in Vivo,” Circulation, Vol. 94, 1996, p. 1611.
[31] L. J. Roberts II and J. D. Morrow, “The Generation and Actions of Isoprostanes,” Biochimica et Biophysica Acta, Vol. 1345, No. 2, 1997, pp. 121-135.
[32] E. Schwedhelm, D. Tsikas, T. Durand, F.-M. Gutzki, A. Guy, J.-C. Rossi and J. C. Fr?lich, “Tandem Mass Spectrometric Quantification of 8-Iso-Prostaglandin F2α and Its Metabolite 2,3-Dinor-8-iso-prostaglandin F2α in Human Urine,” Journal of Chromatography B, Vol. 744, 2000, pp. 9-112.
[33] D. Tsikas, E. Schwedhelm, J. Fauler, F.-M. Gutzki, E. Mayatepek and J. C. Fr?lich, “Specific and Rapid Quantification of 8-Iso-Prostaglandin F2α in Urine of Healthy Humans and Patients with Zellweger Syndrome by Gas Chromatography-Tandem Mass Spectrometry,” Journal of Chromatography B, Vol. 716, 1998, pp. 7-17. doi:10.1016/S0378-4347(98)00275-8